Logo image of ASL.CA

ARGENTUM SILVER CORP (ASL.CA) Stock Fundamental Analysis

TSX-V:ASL - TSX Venture Exchange - CA04014D2068 - Common Stock - Currency: CAD

0.04  0 (0%)

Fundamental Rating

0

Overall ASL gets a fundamental rating of 0 out of 10. We evaluated ASL against 797 industry peers in the Metals & Mining industry. ASL may be in some trouble as it scores bad on both profitability and health. ASL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ASL had negative earnings in the past year.
ASL had a negative operating cash flow in the past year.
In the past 5 years ASL always reported negative net income.
ASL had a negative operating cash flow in each of the past 5 years.
ASL.CA Yearly Net Income VS EBIT VS OCF VS FCFASL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500K -1M -1.5M

1.2 Ratios

ASL has a worse Return On Assets (-411.67%) than 86.95% of its industry peers.
Industry RankSector Rank
ROA -411.67%
ROE N/A
ROIC N/A
ROA(3y)-91.04%
ROA(5y)-91.39%
ROE(3y)-315.37%
ROE(5y)-234.67%
ROIC(3y)N/A
ROIC(5y)N/A
ASL.CA Yearly ROA, ROE, ROICASL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASL.CA Yearly Profit, Operating, Gross MarginsASL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, ASL has about the same amount of shares outstanding.
ASL has more shares outstanding than it did 5 years ago.
ASL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ASL.CA Yearly Shares OutstandingASL.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ASL.CA Yearly Total Debt VS Total AssetsASL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M

2.2 Solvency

ASL has an Altman-Z score of -220.81. This is a bad value and indicates that ASL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASL (-220.81) is worse than 88.21% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -220.81
ROIC/WACCN/A
WACCN/A
ASL.CA Yearly LT Debt VS Equity VS FCFASL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500K -500K

2.3 Liquidity

ASL has a Current Ratio of 0.54. This is a bad value and indicates that ASL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ASL (0.54) is worse than 67.75% of its industry peers.
ASL has a Quick Ratio of 0.54. This is a bad value and indicates that ASL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ASL (0.54) is worse than 65.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
ASL.CA Yearly Current Assets VS Current LiabilitesASL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M

0

3. Growth

3.1 Past

ASL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.25%.
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASL. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASL.CA Price Earnings VS Forward Price EarningsASL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASL.CA Per share dataASL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ASL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ARGENTUM SILVER CORP

TSX-V:ASL (8/5/2025, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)05-23 2025-05-23
Earnings (Next)10-23 2025-10-23
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.06M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -411.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.04%
ROA(5y)-91.39%
ROE(3y)-315.37%
ROE(5y)-234.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -220.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.45%
OCF growth 3YN/A
OCF growth 5YN/A